Heart failure stages ejection fraction
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that heart failure stages and ejection fraction are critical for identifying risk, understanding clinical characteristics, and guiding treatment, with specific attention needed for HFmrEF and the progression from Stage C to Stage D.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Understanding Heart Failure Stages and Ejection Fraction
Heart failure (HF) is a complex clinical syndrome characterized by the heart's inability to pump blood efficiently. The classification of heart failure is often based on the left ventricular ejection fraction (LVEF), which measures the percentage of blood leaving the heart each time it contracts. This article explores the different stages of heart failure and the associated ejection fraction categories.
Heart Failure Stages: A, B, C, and D
Stage A: At Risk for Heart Failure
Stage A includes individuals at high risk for developing heart failure but without structural heart disease or symptoms of HF. Common risk factors include hypertension, diabetes, and coronary artery disease. For instance, diabetes mellitus is a significant risk factor for developing heart failure with preserved ejection fraction (HFpEF).
Stage B: Pre-Heart Failure
Stage B refers to patients with structural heart disease but without signs or symptoms of HF. This stage often includes individuals with left ventricular hypertrophy or previous myocardial infarction. Diabetic cardiomyopathy, characterized by left ventricular diastolic dysfunction in diabetic patients without other potential etiologies, is an example of Stage B HFpEF.
Stage C: Symptomatic Heart Failure
Stage C includes patients with known structural heart disease and current or previous symptoms of HF. This stage is further divided based on ejection fraction:
- Heart Failure with Reduced Ejection Fraction (HFrEF): LVEF ≤ 40%. Patients in this category often progress to more advanced stages of HF, with a significant annual progression rate to Stage D.
- Heart Failure with Mid-range Ejection Fraction (HFmrEF): LVEF 41-49%. This category is considered a "gray zone" and may share characteristics with both HFrEF and HFpEF .
- Heart Failure with Preserved Ejection Fraction (HFpEF): LVEF ≥ 50%. HFpEF patients have a similar poor prognosis as those with HFrEF, with high rates of cardiovascular and HF readmissions.
Stage D: Advanced Heart Failure
Stage D includes patients with refractory HF requiring specialized interventions. These patients have severe symptoms despite optimal medical therapy and are often candidates for advanced therapies such as heart transplantation or mechanical circulatory support. The annual progression rate to Stage D among Stage C HFrEF patients is approximately 4.5%.
Ejection Fraction Categories: HFrEF, HFmrEF, and HFpEF
Heart Failure with Reduced Ejection Fraction (HFrEF)
HFrEF is characterized by an LVEF of 40% or less. Patients with HFrEF have a high risk of progression to advanced stages of HF and significant mortality rates .
Heart Failure with Mid-range Ejection Fraction (HFmrEF)
HFmrEF, with an LVEF between 41% and 49%, is a relatively new classification. It represents a heterogeneous group of patients who may exhibit characteristics of both HFrEF and HFpEF. The clinical management of HFmrEF remains challenging due to the lack of randomized controlled trials specifically targeting this group .
Heart Failure with Preserved Ejection Fraction (HFpEF)
HFpEF is defined by an LVEF of 50% or higher. Despite the preserved ejection fraction, these patients experience significant morbidity and mortality, similar to those with HFrEF. Risk stratification using biomarkers and cardiopulmonary exercise testing can help identify HFpEF patients at increased risk for adverse events .
Conclusion
Heart failure is a progressive disease with distinct stages and varying ejection fraction categories. Understanding these classifications is crucial for effective risk stratification, management, and treatment of HF patients. Future research is needed to better elucidate the pathophysiology and optimal management strategies for HFmrEF and HFpEF, given their complex and heterogeneous nature.
Sources and full results
Most relevant research papers on this topic
